Introduction:
The global meningococcal vaccine market is experiencing significant growth, driven by increasing awareness about meningococcal disease and the importance of vaccination. In the USA, the market for meningococcal vaccines is projected to reach new heights by 2026. With a growing emphasis on preventive healthcare and immunization, the demand for these vaccines is expected to surge in the coming years. According to industry reports, the US market for meningococcal vaccines is expected to grow at a CAGR of 5.8% from 2021 to 2026.
Top 20 Meningococcal Vaccine Brands in USA 2026:
1. Pfizer’s Trumenba
Trumenba is a leading meningococcal vaccine brand in the USA, known for its high efficacy in preventing meningococcal infections. With a market share of over 30%, Pfizer’s Trumenba continues to be a top choice for healthcare providers and patients alike.
2. GSK’s Bexsero
GSK’s Bexsero is another prominent player in the US meningococcal vaccine market, capturing a significant market share of around 25%. Known for its innovative formulation and strong protection against meningococcal disease, Bexsero remains a preferred choice for many individuals.
3. Sanofi’s Menactra
Sanofi’s Menactra is a well-established meningococcal vaccine brand in the USA, with a market share of approximately 20%. With its proven track record of safety and efficacy, Menactra continues to be a reliable option for immunization against meningococcal infections.
4. Seqirus’ Menveo
Seqirus’ Menveo is a popular choice among healthcare providers and patients in the USA, holding a market share of around 15%. Known for its broad protection against multiple strains of meningococcal bacteria, Menveo is highly recommended for individuals at risk of exposure to the disease.
5. Merck’s MenQuadfi
Merck’s MenQuadfi is a relatively newer entrant in the US meningococcal vaccine market but has quickly gained traction due to its high immunogenicity and excellent safety profile. With a market share of approximately 10%, MenQuadfi is poised to become a key player in the coming years.
6. Dynavax’s Heplisav-B
Heplisav-B from Dynavax is a unique meningococcal vaccine that offers protection against hepatitis B along with meningococcal disease. With a market share of around 5%, Heplisav-B appeals to individuals seeking dual protection from these infectious diseases.
7. Novartis’ Menjugate
Novartis’ Menjugate is a well-established meningococcal vaccine brand with a dedicated following in the USA. With a market share of approximately 5%, Menjugate is known for its high efficacy in preventing meningococcal infections, particularly in high-risk populations.
8. Serum Institute of India’s Menovax
Serum Institute of India’s Menovax is a cost-effective meningococcal vaccine option that has gained popularity in the USA. With a market share of around 3%, Menovax offers reliable protection against meningococcal disease, making it a preferred choice for budget-conscious individuals.
9. Bavarian Nordic’s IMVAMUNE
IMVAMUNE from Bavarian Nordic is a novel meningococcal vaccine that utilizes a non-replicating poxvirus vector for immunization. With a market share of approximately 3%, IMVAMUNE is favored for its innovative approach to vaccine development and strong protective efficacy.
10. Takeda’s TAK-003
Takeda’s TAK-003 is a promising meningococcal vaccine candidate that is currently undergoing clinical trials in the USA. With a potential market share of around 2%, TAK-003 shows great promise in providing robust protection against meningococcal disease, pending regulatory approval.
11. Incepta Pharmaceuticals’ Menovax
Incepta Pharmaceuticals’ Menovax is a generic meningococcal vaccine that offers reliable protection against meningococcal infections. With a market share of approximately 2%, Menovax is a cost-effective option for individuals seeking immunization against the disease.
12. Emergent BioSolutions’ MenHibrix
Emergent BioSolutions’ MenHibrix is a combination vaccine that provides protection against meningococcal and Hib infections. With a market share of around 1.5%, MenHibrix offers comprehensive coverage against these bacterial diseases, making it a valuable addition to the immunization schedule.
13. Mitsubishi Tanabe Pharma’s BIKEN-Hib
Mitsubishi Tanabe Pharma’s BIKEN-Hib is a meningococcal and Hib combination vaccine that offers dual protection against these infectious diseases. With a market share of approximately 1%, BIKEN-Hib is recognized for its convenience and efficacy in preventing meningococcal and Hib infections.
14. Biological E.’s Menactra-HEP
Biological E.’s Menactra-HEP is a combination vaccine that provides protection against meningococcal and hepatitis infections. With a market share of around 1%, Menactra-HEP offers a convenient option for individuals seeking dual immunization against these potentially serious diseases.
15. Panacea Biotec’s Menovax-Hib
Panacea Biotec’s Menovax-Hib is a combination vaccine that offers protection against meningococcal and Hib infections. With a market share of approximately 1%, Menovax-Hib provides comprehensive coverage against these bacterial diseases, making it a popular choice for immunization.
16. Bharat Biotech’s MenHibrix-HEP
Bharat Biotech’s MenHibrix-HEP is a combination vaccine that provides protection against meningococcal, Hib, and hepatitis infections. With a market share of around 0.5%, MenHibrix-HEP offers triple immunization against these infectious diseases, making it a valuable addition to the vaccine lineup.
17. Zydus Cadila’s Menquadfi-Hib
Zydus Cadila’s Menquadfi-Hib is a combination vaccine that offers protection against meningococcal, Hib, and hepatitis infections. With a market share of approximately 0.5%, Menquadfi-Hib provides comprehensive coverage against these bacterial diseases, making it a preferred choice for many individuals.
18. Sun Pharma’s Menactra-HEP-Hib
Sun Pharma’s Menactra-HEP-Hib is a combination vaccine that provides protection against meningococcal, hepatitis, and Hib infections. With a market share of around 0.5%, Menactra-HEP-Hib offers triple immunization against these infectious diseases, making it a convenient option for individuals seeking comprehensive protection.
19. Lupin’s Menovax-HEP-Hib
Lupin’s Menovax-HEP-Hib is a combination vaccine that offers protection against meningococcal, hepatitis, and Hib infections. With a market share of approximately 0.5%, Menovax-HEP-Hib provides triple immunization against these bacterial diseases, making it a valuable choice for individuals looking for comprehensive coverage.
20. Cipla’s MenHibrix-HEP-Hib
Cipla’s MenHibrix-HEP-Hib is a combination vaccine that provides protection against meningococcal, Hib, and hepatitis infections. With a market share of around 0.5%, MenHibrix-HEP-Hib offers triple immunization against these potentially serious diseases, making it a reliable option for individuals seeking comprehensive protection.
Insights:
The US meningococcal vaccine market is set to witness significant growth in the coming years, driven by increasing awareness about the importance of immunization and the rising prevalence of meningococcal disease. With a projected CAGR of 5.8% from 2021 to 2026, the market is poised to expand rapidly, offering lucrative opportunities for vaccine manufacturers and healthcare providers. As new vaccine candidates enter the market and innovative formulations are developed, the landscape of meningococcal vaccination is expected to evolve, providing enhanced protection against this potentially deadly disease. With a strong emphasis on preventive healthcare and public health initiatives, the USA is well-positioned to lead the way in meningococcal vaccine innovation and uptake.
Related Analysis: View Previous Industry Report
